Halozyme Therapeutics Inc. (NASDAQ:HALO) finished Friday with a subtraction of -$0.08 to close at $56.90, a downside of -0.14 percent. An average of 768,960 shares of common stock have been traded in the last five days. There was a fall of -$0.93 in the past week, and it reached a new high 29 times over the past 12 months. The last 20 days have seen an average of 1,202,180 shares traded, while the 50-day average volume stands at 1,194,476.
HALO stock has decreased by -0.63% in the last month. The company shares reached their 1-month lowest point of $55.42 on 12/05/22. With the stock rallying to its 52-week high on 12/02/22, shares of the company touched a low of $31.36 and a high of $59.46 in 52 weeks. It has reached a new high 28 times so far this year and achieved 41.51% or $16.69 in price. In spite of this, the price is down -4.31% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
HALO stock investors should be aware that Halozyme Therapeutics Inc. (HALO) stock had its last reported insider trading activity 16 days ago on Dec 15. In this transaction, the insider spent $573,694. PRESIDENT AND CEO, Torley Helen, disposed of 10,000 shares at a price of $58.30 on Dec 14. The insider now owns more than $582,980 worth of shares. Prior to that, PRESIDENT AND CEO Torley Helen went on to Sale 10,000 shares at $58.66 each on Dec 13. An amount of $586,627 was transacted.
Halozyme Therapeutics Inc. (HALO) has a trailing price-to-earnings (P/E) ratio of 38.19. The stock’s beta is 1.22. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 13.33, the price-to-book (PB) ratio at 80.14, and the price-to-cash flow ratio at 32.57.
The quick ratio of Halozyme Therapeutics Inc. for the three months ended June 29 was 5.00, and the current ratio was 6.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 15.37 and a total debt to equity ratio of 15.51 for the quarter ending June 29. Its gross profit as reported stood at $361.9 million compared to revenue of $443.31 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Halozyme Therapeutics Inc.’s return on assets was 14.30%.
For the three-month period that ended June 29, Halozyme Therapeutics Inc. had $118.43 million in cash and short-term investments compared to $1.49 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $61.63 million in the quarter, while revenues of $22.69 million were shrunk -251.44%. The analyst consensus anticipated Halozyme Therapeutics Inc.’s latest quarter earnings to come in at $0.5 per share, but it turned out to be $0.53, a 6.00% surprise. For the quarter, EBITDA amounted to $116.61 million. Shareholders own equity worth $135.21 million.
From a technical analysis perspective, let’s take a brief look at Halozyme Therapeutics Inc. (HALO) price momentum. RSI 9-day as of the close on 30 December was 49.73%, suggesting the stock is Neutral, with historical volatility in this time frame at 18.82%.
As of today, HALO’s price is $57.05 -1.61% or -$0.93 from its 5-day moving average. HALO is currently trading -0.87% lower than its 20-day SMA and +31.32% higher than its 100-day SMA. However, the stock’s current price level is +29.47% above the SMA50 and +57.75% above the SMA200.
The stochastic %K and %D were 32.98% and 35.84%, respectively, and the average true range (ATR) was 1.46. With the 14-day stochastic at 33.69% and the average true range at 1.53, the RSI (14) stands at 54.66%. The stock has reached -0.27 on the 9-day MACD Oscillator while the 14-day reading was at -0.53.
The consensus rating for Halozyme Therapeutics Inc. (HALO) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell HALO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is HALO’s price target for the next 12 months?
Analysts predict a range of price targets between $23.00 and $68.00, with a median target of $62.00. Taking a look at these predictions, the average price target given by analysts for Halozyme Therapeutics Inc. (HALO) stock is $56.00.